Pharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects

ConclusionVedolizumab was well tolerated in healthy Chinese subjects when administered as a single-dose IV 300  mg infusion. In this study, the rate of AVA positivity was 37.5%, which occurred near the end of the study; no significant differences in pharmacokinetic profiles were observed between the AVA-positive and AVA-negative groups.Clinical Trial Registrationhttp://www.chinadrugtrials.org.cn: CTR20171528.
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research